Riik: Austraalia
keel: inglise
Allikas: Department of Health (Therapeutic Goods Administration)
clarithromycin
Amneal Pharma Australia Pty Ltd
Clarithromycin
Registered
_Clarithromycin AN tablets – Consumer Medicine Information _ _ _ _Doc ID: 51.AN.M.1.0 _ _ _ _ _ _Page 1 _ CLARITHROMYCIN AN TABLETS _Clarithromycin _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Clarithromycin AN tablets. It does not contain all of the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking CLARITHROMYCIN AN against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT CLARITHROMYCIN AN IS USED FOR CLARITHROMYCIN AN IS USED TO TREAT CERTAIN BACTERIAL INFECTIONS, INCLUDING THE FOLLOWING: RESPIRATORY TRACT INFECTIONS SKIN INFECTIONS PEPTIC ULCER CLARITHROMYCIN AN is also used to prevent a specific bacterial infection associated with HIV infection. Your doctor, however, may have prescribed CLARITHROMYCIN AN for another purpose. Ask your doctor if you have any questions about why CLARITHROMYCIN AN has been prescribed for you. CLARITHROMYCIN AN IS AN ANTIBIOTIC THAT BELONGS TO THE GROUP OF MEDICINES CALLED MACROLIDES. THESE MEDICINES WORK BY KILLING OR STOPPING THE GROWTH OF BACTERIA WHICH CAUSE INFECTIONS. CLARITHROMYCIN AN WILL NOT WORK AGAINST INFECTIONS CAUSED BY VIRUSES, SUCH AS COLDS OR FLU. CLARITHROMYCIN AN IS AVAILABLE ONLY WITH A DOCTOR’S PRESCRIPTION. CLARITHROMYCIN AN TO TREAT PEPTIC ULCER Peptic ulcers are associated with an infection in the intestine and stomach by a bacteria called _Helicobacter _ _pylori_ (_H. _ _pylori_). Nearly all patients with peptic ulcers are infected with this bacteria. The _ H. pylori_ infection can be treated with a combination of CLARITHROMYCIN AN (clarithromycin), another antibiotic (amoxycillin) and another medicine called omeprazole (used to control the acidity of the stomach). However, the best combination of tablet Lugege kogu dokumenti
_Clarithromycin AN tablets Product Information _ _ _ _Amneal Pharma Australia Pty Ltd _ Clarithromycin AN PI v.3.0 Page 1 CLARITHROMYCIN AN _ _ _(CLARITHROMYCIN TABLETS) _ _ _ PRODUCT INFORMATION _ _ NAME OF THE MEDICINE The name of the medicine is clarithromycin. CHEMICAL NAME: (3 _R_ ,4 _S_ ,5 _S_ ,6 _R_ ,7 _R_ ,9 _R_ ,11 _R_ ,12 _R_ ,13 _S_ ,14 _R_ )-4-[(2,6-Dideoxy-3- _C_ - methyl-3- _O_ - methyl-α- L - _ribo_ -hexopyranosyl)oxy]-14-ethyl-12,13-dihydroxy-7-methoxy-3,5,7,9,11,13- hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-β-D- _xylo_ - hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione (6- _O_ -methylerythromycin A) MOLECULAR FORMULA: C 38 H 69 NO 13 MOLECULAR WEIGHT: 747.97 CAS REGISTRY NUMBER: _[81103-11-9] _ DESCRIPTION Clarithromycin is a semi-synthetic macrolide antibiotic. Clarithromycin is a white to off- white crystalline powder. It is soluble in acetone, slightly soluble in methanol, ethanol and acetonitrile, and practically insoluble in water. Other ingredients in Clarithromycin AN 250 mg Tablets are microcrystalline cellulose, pregelatinised maize starch, croscarmellose sodium, povidone, stearic acid, magnesium stearate, colloidal anhydrous silica, quinoline yellow, Opadry White Y-1-7000 (containing hypromellose, titanium dioxide and Macrogol 400), Quinoline yellow aluminium lake, hypromellose and vanillin. PHARMACOLOGY Hepatotoxicity, atrophy of lymphatic tissues (lymph, thymus) and adverse reproductive toxicity were seen in several species at exposures less than those which might be expected clinically at the proposed doses. The clinical significance of these observations is not known. _Clarithromycin AN tablets Product Information _ _ _ _Amneal Pharma Australia Pty Ltd _ Clarithromycin AN PI v.3.0 Page 2 There are no data from long term animal carcinogenicity studies. _Clinical Pharmacokinetics: _ Clarithromycin is absorbed from the gastrointestinal tract after oral administration. The absolute bioavailability of 250 mg tablets is approximately 50%. Food intake half an hour before tablet dos Lugege kogu dokumenti